Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on
hepatorenal syndrome treatment market provides an in-depth analysis of segments
and sub-segments in the global as well as regional hepatorenal syndrome
treatment market. The study also highlights the impact of drivers, restraints,
and macro indicators on the global and regional hepatorenal syndrome treatment
market over the short term as well as long term. The report is a comprehensive
presentation of trends, forecast and dollar values of the global hepatorenal
syndrome treatment market. According to the report, the global hepatorenal
syndrome treatment market is projected to grow at a CAGR of 4.8% over the
forecast period of 2019-2025.
Hepatorenal syndrome is a functional and reversible form of
renal failure in patients with advanced chronic liver diseases. It is the most
severe complication of cirrhosis. Hepatorenal syndrome is almost always fatal. Hepatorenal syndrome patients commonly have a
variety of symptoms such as weakness, abdominal pain, and discomfort. To
prevent Hepatorenal syndrome, several therapeutics and surgical treatments are
available in the market.
The growing awareness regarding Hepatorenal syndrome diagnosis
and treatment thereby stimulating the growth of the global market for the
treatment of Hepatorenal syndrome. Additionally, growing incidences of
hepatorenal syndrome are also boosting the growth of the market. It is estimated that near about 40% of
patients with stage 4 or 5 of chronic kidney disease receive simultaneous
liver-kidney transplants (SLKs), according to the Clinical Journal of American
Society of Nephrology (CJASN) 2017. Moreover, increasing support from the
government regarding campaigns program to improve hepatorenal syndrome care is
likely to enhance the growth of the market. Further, Nowadays, Pharmaceuticals
companies operating in this market are developing therapeutic drugs that are
safe and effective for Hepatorenal syndrome patients. For instance, In August
2019, Mallinckrodt plc, a global biopharmaceutical company, announced the
launch of terlipressin for the treatment of hepatorenal syndrome type 1
(HRS-1). Furthermore, increasing
research and development by the companies to reduce economies burden on
patients, and the availability of advanced treatment options at U.S. hospitals
augment the demand of the market. For instance, it is estimated that the cost of
treatment for HRS is less expensive in India as compared to the developed
countries. However, the high cost of treatment is expected to hamper the growth
of the global hepatorenal syndrome treatment market over the forecast period. Moreover, the launch of various pipeline drugs for the treatment of hepatorenal syndrome in
the coming years creates growth opportunities for the market
Among the geographies, the global hepatorenal syndrome
treatment market is bifurcated into North America, Europe, Asia Pacific, and
Row. North America dominates the global hepatorenal syndrome treatment market.
Moreover, an estimated 12,000 to 33,000 Americans develop HRS each year.
The factors such as increasing incidences of HRS, well-developed healthcare
infrastructures and the launch of new pipeline drugs in this region propelling
the growth of North America hepatorenal syndrome treatment market. Favorable
reimbursement policies for chronic kidney disease patients are likely to have a
positive impact on regional growth. Further, the U.S. is accounted for the
largest revenues in this market. On the other hand, developing countries of
Asia Pacific hold great opportunities for the hepatorenal syndrome treatment
market due to their growth in population coupled with growing healthcare
expenditure.
The report on the global hepatorenal syndrome treatment market
covers segments such as type, treatment, and end user. On the basis of type,
the sub-markets include type 1 hepatorenal syndrome, and type 2 hepatorenal
syndrome. On the basis of treatment, the sub-markets include therapeutics, and
surgical treatment. On the basis of end user, the sub-markets include hospitals
& clinics, ambulatory surgical centers, academic & research institutes,
and other end-users.
Companies Profiled:
The report provides profiles of the companies in the market
such as Mallinckrodt Pharmaceuticals, BioVie, Cumberland Pharmaceuticals Inc,
Orphan Therapeutics, LLC, and Other Companies.
Report Highlights:
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of the hepatorenal
syndrome treatment market. Moreover, the study highlights current market trends
and provides forecast from 2019-2025. We also have highlighted future trends in
the market that will affect the demand during the forecast period. Moreover,
the competitive analysis given in each regional market brings an insight into
the market share of the leading players.
Please Choose One of them.